KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 86 filers reported holding KINNATE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $88,144 | +4.5% | 14,103 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $84,314 | -49.2% | 13,822 | -0.4% | 0.00% | 0.0% |
Q3 2022 | $166,000 | -3.5% | 13,872 | +1.4% | 0.00% | 0.0% |
Q2 2022 | $172,000 | +19.4% | 13,677 | +7.0% | 0.00% | 0.0% |
Q1 2022 | $144,000 | -40.5% | 12,778 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $242,000 | -25.3% | 13,678 | -2.9% | 0.00% | -50.0% |
Q3 2021 | $324,000 | +83.1% | 14,087 | +85.4% | 0.00% | +100.0% |
Q2 2021 | $177,000 | -27.8% | 7,598 | -3.5% | 0.00% | 0.0% |
Q1 2021 | $245,000 | – | 7,877 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 3,525,957 | $4,936,340 | 7.88% |
Foresite Capital Management IV, LLC | 9,671,643 | $13,540,300 | 7.52% |
Vida Ventures Advisors, LLC | 2,207,772 | $3,090,881 | 4.78% |
Lynx1 Capital Management LP | 1,997,006 | $2,795,808 | 1.85% |
Nextech Invest Ltd. | 2,329,480 | $3,261,272 | 0.99% |
Orbimed Advisors | 8,009,729 | $11,213,621 | 0.24% |
Novo Holdings A/S | 815,707 | $1,141,990 | 0.08% |
DAFNA Capital Management LLC | 105,179 | $147,251 | 0.05% |
GSA CAPITAL PARTNERS LLP | 374,291 | $524 | 0.04% |
Rock Springs Capital Management LP | 405,811 | $568,135 | 0.02% |